FilingReader Intelligence

Walvax Biotechnology reports revenue decline, significant net profit drop in Q1

April 26, 2025 at 05:59 AM UTC•By FilingReader AI

Walvax Biotechnology (SZSE:300142) announced a 22.93% year-over-year decrease in revenue, reporting CNY462.26 million for Q1 2025, compared to CNY599.75 million in the same period last year. Net profit attributable to shareholders plummeted 81.27% to CNY2.65 million from CNY14.13 million. Basic and diluted earnings per share both decreased by 80.68% to CNY0.0017.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

Primary Source Document

Announcement on the Provision for Asset Impairment and Asset Write-offs in the First Quarter of 2025April 25, 2025 at 08:00 AM UTC

Supplementary Source Documents

Announcement on the Provision for Asset Impairment and Asset Write-offs in the First Quarter of 2025April 25, 2025 at 09:40 AM UTC

Walvax Biotechnology

SZSE:300142•Shenzhen Stock Exchange

Pharmaceuticals

RSS feed for Walvax Biotechnology

News Alerts

Get instant email alerts when Walvax Biotechnology publishes news

Free account required • Unsubscribe anytime

Browse RSS Feeds

Filing Activity Timeline

View Complete Filing History →